Design: A decision analysis model of cost-utility PARTICIPANTS: Data from study participants in the Lucentis, Eylea, Avastin in Vein Occlusion (LEAVO) study. Methods: A decision analysis of a disease simulation model was used to calculate comparative cost-utility of intravitreal bevacizumab (IVB),...
The analysis included 624 patients randomized to Eylea (aflibercept, Regeneron), Avastin (bevacizumab, Genentech) or Lucentis (ranibizumab, Genentech). Based on 2015 wholesale acquisition costs, the cost of aflibercept 2 mg was $1,850, ranibiz...
In the Kaiser study, the frequency of adverse events did not differ between treatment groups, but Avastin patients received fewer injections over the course of a year. "What this article principally does is that it reassures patients and ophthalmologists that Avastin appears to be just as effectiv...
In light of these new data, the present study was conducted with the goal of evaluating the cost-effectiveness of olaparib plus bevacizumab for the treatment of the overall AOC patient population and for homologous recombination deficiency (HRD)-positive patients, patients with a breast cancer ...
Avastin could potentially result in huge cost savings in the UKAge-related-macular-degeneration, treatmentBevacizumab, therapeutic useEconomic-implicationsHealth-policyRanibizumab, therapeutic useReimbursementThe article discusses research on the effectiveness of avastin for treating wet age-related macular ...
Bevacizumab (Avastin, Genentech, Inc) is not cost-effective as a first-line treatment for newly diagnosed glioblastoma owing to its limited impact on patient outcomes, the results of a Canadian analysis indicate. Using published trial data, the investigators found that achieving a single quality-adj...
1 Zaltrap had been priced at an average of about $11,000 a month, while Avastin costs less than half that at around $5000 per month. Subsequently, Sanofi discounted the net cost of Zaltrap by 50% in the United States in response to market resistance.5 Amid concerns with the high cost ...
Avastin Increases PFS in Patients With Ovarian Cancer New FDA-Approved Oncology Drugs and Indications, 2011 The Year's New Drugs: Integrating Advances of 2011 Into Treatment Plans Overcoming Resistance to Endocrine Therapies Keeping Patients in Mind: Noted Breast Cancer Researcher Pursues Broad Notion ...
Schmucker C,Loke YK,Ehlken C,et al.Intravitreal bevacizumab (Avastin)versus ranibizumab (Lucentis)for the treatment of age-related macular degeneration:a ... C Schmucker,YK Loke,C Ehlken,... - 《Br J Ophthalmol》 被引量: 183发表: 2011年 Tachyphylaxis during treatment of exudative age-rela...
By law, Medicare cannot reject any treatment based upon cost. It will pay $55,000 for patients with advanced breast cancer to receive the chemotherapy drug Avastin, even though it extends life only an average of a month and a half; it will pay $40,000 for a 93-year-old man with term...